Search clinical trials for: KA2237

Total 28 results

Karus Therapeutics Limited

Completed

The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

Lymphoma, B Cell

United States
Karus Therapeutics Limited
University College, London

Withdrawn

A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer

Biliary Tract Cancer

United Kingdom
Karus Therapeutics Limited

Completed

Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (HDAC6i)

Solid Tumor, Adult

United States
European Organisation for Research and Treatment...
Bayer; Latin American Cooperative Oncology Group; UNICANCER; Astellas Pharma Europe... and other collaborators

Active, not recruiting

Phase III Radium 223 mCRPC-PEACE III (PEACE III)

Prostate Cancer

Spain, Belgium, France, Italy, United Kingdom, Denmark, Canada, Ireland, Brazil, Norway, Poland, Switzerland
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

United States, Korea, Republic of, Malaysia, Turkey, Bulgaria, Canada, Poland, Puerto Rico, Romania, Croatia, Georgia, Italy, Philippines, Taiwan, Ukraine
Biohaven Pharmaceuticals, Inc.
Dana-Farber Cancer Institute

Recruiting

Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients

Multiple Myeloma

United States
Novartis Pharmaceuticals

Completed

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Type-2 Diabetes Mellitus

Hong Kong
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

Spain, Italy, United States, Japan, Poland, Taiwan, Germany, United Kingdom, Hungary, France, Ukraine
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients. (BENEFIT)

Type 2 Diabetes Mellitus

Germany
University Hospital, Gasthuisberg

Completed

Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer (LiverMWA1)

Liver Neoplasms

Belgium
Triangle Pharmaceuticals

Completed

A Study of MKC-442 in HIV-Positive Patients

HIV Infections
Novartis

Terminated

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers

Healthy

China
Novartis Pharmaceuticals

Completed

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Type 2 Diabetes

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers

Healthy

China
Novartis Pharmaceuticals

Completed

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Spain, Poland, South Africa, Taiwan, Hong Kong, Norway, Italy, Bulgaria, Latvia, Lithuania, Germany, Turkey, Argentina, Israel, Korea, Republic of, Dominican Republic, Guatemala, Brazil, Colombia, Peru, Philippines, Russian Federation and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Mayo Clinic
Novartis Pharmaceuticals

Completed

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
Novartis

Completed

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Type-2 Diabetes

Germany, United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Taiwan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China, Thailand, Philippines, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia

Diabetes Mellitus, Type 2

Switzerland, Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Type 2 Diabetes Mellitus (T2DM)

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function (CGM-VISIT)

Diabetes Mellitus Type 2

Germany
Novartis Pharmaceuticals

Completed

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan

3

Subscribe